# Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

> **NCT05651100** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Kecellitics Biotech Company Ltd** · enrollment: 50 (estimated)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **BIOLOGICAL:** CD19 and CD22 targeted CAR-T cells

## Key facts

- **NCT ID:** NCT05651100
- **Lead sponsor:** Kecellitics Biotech Company Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-10
- **Primary completion:** 2024-12-10
- **Final completion:** 2025-12-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05651100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05651100, "Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05651100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*